|
|
Blood, 1 January 2004, Vol. 103, No. 1, pp. 143-151.
Prepublished online as a Blood First Edition Paper on September 11, 2003; DOI 10.1182/blood-2003-06-2181.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs
Jun Zhang,
Lingfei Xu,
Mark E. Haskins, and
Katherine Parker Ponder
From the Departments of Internal Medicine and Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, MO; and the Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia.
The effect of neonatal gene transfer on antibody formation was determined using a retroviral vector (RV) expressing human factor IX (hFIX). Normal mice from different strains injected intravenously with RV as newborns achieved therapeutic levels of hFIX without antibody production and were tolerant as adults to challenge with hFIX. Neonatal hemophilia B mice that received different amounts of RV achieved stable and dose-related expression of hFIX without anti-hFIX antibody formation. After protein challenge, antibody formation was markedly reduced for animals that expressed hFIX at levels higher than 14 ng/mL (0.3% of normal). However, antibodies developed for animals that received the lowest dose of RV and expressed hFIX at approximately 2 ng/mL before protein challenge. In dogs, neonatal injection of a high dose of RV resulted in 500 ng/mL hFIX in plasma without antibody formation. We conclude that neonatal gene transfer with RV does not induce antibody responses to hFIX in mice or dogs and that mice achieving levels greater than 3 x 10–10 M hFIX are usually tolerant to protein injection as adults. Low-dose gene therapy or frequent protein injections in the neonatal period might induce tolerance to subsequent injections of protein with a low risk for adverse effects.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. Cao, E. Dobrzynski, L. Wang, S. Nayak, B. Mingle, C. Terhorst, and R. W. Herzog
Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer
Blood,
August 15, 2007;
110(4):
1132 - 1140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Cao, E. Armstrong, A. Schlachterman, L. Wang, D. K. Okita, B. Conti-Fine, K. A. High, and R. W. Herzog
Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX
Blood,
July 15, 2006;
108(2):
480 - 486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Dobrzynski, J. C. Fitzgerald, O. Cao, F. Mingozzi, L. Wang, and R. W. Herzog
Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells
PNAS,
March 21, 2006;
103(12):
4592 - 4597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Dobrzynski and R. W. Herzog
Tolerance Induction by Viral In Vivo Gene Transfer
Clin. Med. Res.,
November 1, 2005;
3(4):
234 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Xu, T. C. Nichols, R. Sarkar, S. McCorquodale, D. A. Bellinger, and K. P. Ponder
Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy
PNAS,
April 26, 2005;
102(17):
6080 - 6085.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. Waddington, M. S. Nivsarkar, A. R. Mistry, S. M. K. Buckley, G. Kemball-Cook, K. L. Mosley, K. Mitrophanous, P. Radcliffe, M. V. Holder, M. Brittan, et al.
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy
Blood,
November 1, 2004;
104(9):
2714 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
